Summary
Every living cell needs energy to survive. The process that generates this cellular fuel is called glycolysis. Because infectious microbes like Staphylococcus aureus (a dangerous bacterium) and Plasmodium vivax (a parasite that causes malaria) rely heavily on this process, scientists have long wanted to shut it down to cure infections. The problem is that human cells use glycolysis too. Traditional drugs that block the main engine of this energy process often end up harming patients along with the infection.
To solve this, researchers used advanced computer models to look for alternative weak points, known as allosteric sites. Think of these as hidden control switches located away from the main active area of the enzyme. By mapping all ten enzymes involved in the glycolysis process for both the bacterium and the malaria parasite, the team found switches that look very different from the ones in human cells. This difference is crucial because it means future drugs could hit these targets to starve the bugs without hurting the human host.
Using computer simulations, the team screened over 1,600 existing, FDA-approved drugs to see if any could latch onto these newly mapped hidden switches. They identified compounds capable of binding to multiple targets at once, effectively shutting down the entire microbial energy pathway. However, the scientists caution that this is early work. Because the study relies heavily on computer modeling and virtual screening, researchers will need to test these drugs in physical lab experiments and living models to confirm they work as predicted.
Why it matters.
Finding new ways to fight Staphylococcus aureus and Plasmodium vivax is a major priority for global health. These pathogens cause serious, often deadly infections, and they are becoming increasingly resistant to existing antibiotic and antimalarial treatments. By discovering a way to safely choke off their energy supply without causing toxic side effects in humans, this research provides a fresh blueprint for designing the next generation of safe, effective medicines.
Furthermore, the strategy of hitting multiple enzyme targets at once makes it much harder for microbes to mutate and develop resistance. If these early computer predictions hold up in physical trials, this method could dramatically speed up the drug discovery process. By repurposing medications that are already FDA-approved and proven safe in humans, pharmaceutical researchers could potentially shave years off the development timeline and save billions of dollars.
The story in numbers.
- Glycolytic enzymes mapped
- 10
- FDA-approved compounds virtually screened
- 1,615
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.